Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Rectal cancer
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Treatment options === ** Long course chemoradiotherapy (LC-CRT) *** Indicated for T1/2N0 disease *** Chemotherapy just given as a radiosensitiser - fluoropyrimidines or capecitabine on days of radiotherapy *** 50.4-54 Gy total, administered over 28-31 daily fractions *** Aim to operate either 6-10 weeks afterwards or >6 months afterwards - initial oedema makes it hard, then fibrosis makes it hard, then that settles ** Short-course radiotherapy *** 25 Grays (5 days of 5), then wait another week, then operate *** Comparable to long-course with local recurrence DFS, distal recurrence, OS and toxicity *** More long-term side effects than surgery alone *** Not favoured, not usually done unless in special circumstances (won't tolerate full course, synchronous metastatic lesions to minimise delays) ** Neoadjuvant immunotherapy *** Option for patients with dMMR cancer *** Immunotherapy then re-stage *** No CTX or CRT unless progression/no response ** Total neoadjuvant therapy for locally advanced tumours (TNT) *** Indications: T4, N2, <5cm from anal verge, threatened mesorectal margin, extramural venous invasion *** Need an adequate performance status, more so than for CRT alone *** Neoadjuvant oxaliplatin-based chemotherapy for 12-16 weeks (FOLFIRINOX, FOLFOX or CAPOX) plus radiotherapy (usually long-course radiotherapy and capecitabine) **** FOLFIRINOX has the best outcomes but also the most toxic *** Usually start with chemotherapy, although the optimal sequencing has not been established *** This has been shown to significantly improve pathological complete response rate from about 14% with long-course CRT to about 28% with TNT (RAPIDO and PRODIGE 23 trials) ** Neoadjuvant chemotherapy + selective use of CRT *** T2N1, T3N0, T3N1 and eligible for sphincter-sparing surgery *** The favoured modern approach - start off with systemic therapy for three months, then restage and give RTX if no/minimal response *** CAPOX and FOLFOX can be used if the patient has lower performance status; FOLFIRINOX can be used if the patient has better performance status. **** '''The difference between this and TNT is that here you aren't committed to CRT - restage after CTX, and if good response, go straight to operation''' **
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Rectal cancer
(section)
Add topic